<DOC>
	<DOCNO>NCT02600390</DOCNO>
	<brief_summary>SANGUINATE™ Sickle Cell Disease associate Leg Ulcers .</brief_summary>
	<brief_title>SANGUINATE™ Sickle Cell Disease Associated Leg Ulcer</brief_title>
	<detailed_description>This escalating , repeated-dose , open-label Phase 2 study test SANGUINATE ( pegylated carboxyhemoglobin bovine ) patient suffer leg ulceration associate Sickle Cell Disease ( SCD leg ulcer ) . Patients undergo consent screen procedure time presentation leg ulcer treatment . Eligible patient begin 3-week Run-In Period . A total approximately fifteen ( 15 ) patient expect screened order achieve enrollment target ten ( 10 ) evaluable patient participation study . Evaluable defined patient receive minimum three dos investigational product . Five ( 5 ) patient ( Cohort 1 ) receive four ( 4 ) once-weekly 2-hour IV infusion SANGUINATE dose 320 mg/kg ( 8 mL ) . An additional five ( 5 ) patient ( Cohort 2 ) receive six ( 6 ) once-weekly 2-hour IV infusion SANGUINATE also dose 320 mg/kg . Each patient contact telephone approximately 24 hour dose verify safety status patient . One week follow Treatment Phase , patient return study center Final Visit safety assessment perform . During Final Visit , patient receive standard care treatment ulcer . All patient receive once-weekly Standard Care ( SOC ) therapy SCD leg ulcer duration study . SOC include dress wound multi-layer , short stretch , compression bandaging . Non-adherent , medical-grade foam use wound contact layer primary dressing .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<criteria>Properly consent patient suffer Sickle Cell Disease ( HbSS Hb Sβ° genotype ) associate Leg ulcer . Presence leg ulcer least 4 week Venous Clinical Severity Score moderate severe ( defined ≥12 ) Leg ulcer knee Patient present clinically &amp; laboratory confirm bacterial , fungal acid fast organisms Patient recent acute complication Sickle Cell Disease ( e.g. , pain crisis within 7 day , acute chest syndrome within 21 day ) Patient plan pregnant , pregnant , breastfeed Presence moderate severe renal insufficiency ( CrCl &lt; 30 mL/min ) chronic kidney disease , moderate severe hepatic insufficiency ( ChildPugh class B C ) Patients 3 time upper limit normal laboratory reference range Concurrent recent prior treatment ( within 90 day ) investigational medication Patients currently receive treatment hydroxyurea must stable dose least 30 day Receipt blood transfusion within 21 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Leg Ulcer</keyword>
	<keyword>LU</keyword>
	<keyword>SANGUINATE</keyword>
	<keyword>QOL</keyword>
	<keyword>SCD</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Sickle Cell</keyword>
	<keyword>Anemia</keyword>
	<keyword>Leg Wound</keyword>
	<keyword>Leg</keyword>
	<keyword>Skin Lesion</keyword>
</DOC>